Cyduct Diagnostics To Participate at the 10th Annual Yale Innovation Summit
CYduct Diagnostics will present at the 2024 Yale Innovation Summit on May 29-30 in New Haven, CT. The company, specializing in non-invasive intraductal breast health technology, will showcase study data on its proteomic technology, which aims to enhance breast cancer detection and patient care. The Summit, celebrating its 10th year, is a major event in the innovation sector, featuring industry leaders from various fields. CYduct's CEO, Dom Gatto, highlighted the benefits of molecular innovations, emphasizing the company's role in improving diagnostic accuracy, reducing unnecessary surgeries, and enhancing early detection and treatment of breast cancer.
- CYduct Diagnostics' participation in the 2024 Yale Innovation Summit raises its profile among key industry leaders and investors.
- The company will present data on proteomic technology, which could significantly improve breast cancer detection and patient care.
- CYduct's focus on non-invasive, precision breast health solutions aligns with current healthcare trends favoring less invasive and more accurate diagnostics.
- Intraductal techniques promoted by CYduct have the potential to lower unnecessary surgeries, benefiting both patients and healthcare providers.
- The press release does not provide specific financial data or projections, which could leave investors seeking concrete performance metrics.
- There is no mention of regulatory approvals or commercial availability of the proteomic technology, raising questions about its readiness for market.
Yale Innovation Summit, May 29-30, New Haven, CT.
WESTPORT, CT / ACCESSWIRE / May 16, 2024 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct", "CYductDX", or the "Company"), an innovator in precision breast health enabled by non-invasive intraductal platforms, today announced it is pleased to present at the 2024 Yale Innovation Summit, being held from May 29-30 in New Haven, CT. The 10th annual event will feature industry-leading speakers from the arts, biotech, climate, health, and technology sectors.
The Yale Innovation Summit brings together the innovation and entrepreneurship community for two days of impactful conversations, purposeful networking, and Yale pitch competition across five tracks of programming. Celebrating its 10th year, the event has become one of the region's biggest and most impactful innovation events, drawing investors, founders, and industry partners to Yale's campus from around the world to create new connections and opportunities.
CYductDX, will present study data illustrating how proteomic technology can enhance breast cancer detection and improve early detection and patient care at this year's Yale Innovation Summit.
"Across the spectrum of recent healthcare advancements, molecular innovations have proven to be more accurate, less invasive and less expensive than current standards of care," said Dom Gatto, CEO, CYductDX. "We are reshaping the breast healthcare landscape by bringing precision, non-invasive solutions and better options to women. Intraductal techniques have been shown to improve diagnostic accuracy, lower the rate of unnecessary surgeries and improve the ability of clinicians to identify and treat breast cancer early."
About the Yale Innovation Summit:
The Yale Innovation Summit is a two day-long event tailored to innovators to encourage the sharing of new discoveries and technologies with market potential with the broader investment community. It is Connecticut's biggest entrepreneurship event, convening innovators, investors, and industry for panels, speakers, and networking in the arts, biotech, climate, health, and technology.
For more information please visit: https://ventures.yale.edu/community/yale-innovation-summit Or https://bit.ly/3y1jwpG
About CYduct Diagnostics, Inc.:
At CYduct Diagnostics, Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. Its mission is to empower women and their care team to advance breast wellness through personalized risk assessment and early detection of breast cancer. As an innovative healthcare company, its aim is to develop, produce and market leading-edge solutions for unmet clinical needs within Women's Healthcare. The Company's products and services will help to assess and diagnose breast cancer at its earliest stages, allowing for better clinical decisions, thus enhancing women's health and quality of life. The Company does this in a responsible and ethical manner with a commitment to excellence in every aspect of its business.
Additional information on its line of products will be available on the Company's website at: www.CYductDX.com.
FORWARD-LOOKING STATEMENTS; ADDITIONAL INFORMATION
This press release includes certain information that may constitute forward-looking statements. Forward-looking statements are typically identified by terminology such as "could," "may," "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "proposed," "planned," "potential" and similar expressions, or are those, which, by their nature, refer to future events. All statements, other than statements of historical fact, included herein, including statements about CYduct's beliefs and expectations, are forward-looking statements. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Although CYduct believes that such statements are reasonable, it can give no assurance that such forward-looking information will prove to be accurate. CYduct cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors. Accordingly, due to the risks, uncertainties and assumptions inherent in forward-looking information, readers and prospective investors in the Company's securities should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof and is subject to change. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company assumes no obligation to revise or update forward-looking information to reflect new circumstances, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT:
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.
View the original press release on accesswire.com
FAQ
What is CYduct Diagnostics presenting at the 2024 Yale Innovation Summit?
When and where is the 2024 Yale Innovation Summit taking place?
What is the significance of CYduct Diagnostics' technology?
Who is the CEO of CYduct Diagnostics, and what did he say about the company's innovations?
What are the benefits of CYduct Diagnostics' intraductal techniques?
